Literature DB >> 11528419

The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

C Nilsberth1, A Westlind-Danielsson, C B Eckman, M M Condron, K Axelman, C Forsell, C Stenh, J Luthman, D B Teplow, S G Younkin, J Näslund, L Lannfelt.   

Abstract

Several pathogenic Alzheimer's disease (AD) mutations have been described, all of which cause increased amyloid beta-protein (Abeta) levels. Here we present studies of a pathogenic amyloid precursor protein (APP) mutation, located within the Abeta sequence at codon 693 (E693G), that causes AD in a Swedish family. Carriers of this 'Arctic' mutation showed decreased Abeta42 and Abeta40 levels in plasma. Additionally, low levels of Abeta42 were detected in conditioned media from cells transfected with APPE693G. Fibrillization studies demonstrated no difference in fibrillization rate, but Abeta with the Arctic mutation formed protofibrils at a much higher rate and in larger quantities than wild-type (wt) Abeta. The finding of increased protofibril formation and decreased Abeta plasma levels in the Arctic AD may reflect an alternative pathogenic mechanism for AD involving rapid Abeta protofibril formation leading to accelerated buildup of insoluble Abeta intra- and/or extracellularly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528419     DOI: 10.1038/nn0901-887

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  354 in total

1.  Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.

Authors:  Kenjiro Ono; Margaret M Condron; David B Teplow
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 2.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

3.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

4.  Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease.

Authors:  Anna Lord; Ola Philipson; Therése Klingstedt; Gunilla Westermark; Per Hammarström; K Peter R Nilsson; Lars N G Nilsson
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

5.  A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish.

Authors:  Andrea Geling; Harald Steiner; Michael Willem; Laure Bally-Cuif; Christian Haass
Journal:  EMBO Rep       Date:  2002-07       Impact factor: 8.807

6.  Kinetic control of dimer structure formation in amyloid fibrillogenesis.

Authors:  Wonmuk Hwang; Shuguang Zhang; Roger D Kamm; Martin Karplus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

7.  Molecular dynamics simulation of amyloid beta dimer formation.

Authors:  B Urbanc; L Cruz; F Ding; D Sammond; S Khare; S V Buldyrev; H E Stanley; N V Dokholyan
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

Review 8.  The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease.

Authors:  Ekaterina Rogaeva
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 9.  The neurodegeneration in Alzheimer disease and the prion protein.

Authors:  Gianluigi Forloni; Alessandra Sclip; Tiziana Borsello; Claudia Balducci
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

10.  Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.

Authors:  Samir Kumar-Singh; Patrick Cras; Rong Wang; John M Kros; Johan van Swieten; Ursula Lübke; Chantal Ceuterick; Sally Serneels; Krist'l Vennekens; Jean-Pierre Timmermans; Eric Van Marck; Jean-Jacques Martin; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.